3 reasons to buy the FTSE 100’s AstraZeneca stock now

Here’s why I’d be keen to get a solid-looking business such as AstraZeneca into my long-term diversified portfolio right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Scientist filling a needle

Image source: Getty Images.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

FTSE 100 biopharmaceutical company AstraZeneca (LSE: AZN) is still around 19% down from its highs of last year. And with the share price near 7,564p the valuation looks modest considering the growth potential on offer.

The forward-looking earnings multiple for 2022 is around 16. And at least three reasons for buying the stock spring to my mind.

3 reasons to buy AstraZeneca stock

Firstly, the business is delivering strong growth in earnings. Over recent years, the research and development pipeline has been spitting out decent commercial pharmaceutical products. And there could be many more to come.

City analysts expect earnings to knock the ball out of the park in 2021 and increase by around 170% year-on-year. Then in 2022, they’ve pencilled in an earnings increase knocking on the door of 30%. Beyond that, we’ll have to wait and see. But AstraZeneca has rediscovered its growth mojo. And the company could be heading for a bright future.

A second reason for buying the stock is AstraZeneca’s modest level of debt on the balance sheet. What you see is what you get with the valuation and it’s not obscured by buckets full of borrowings. FTSE 100 peer GlaxoSmithKline, on the other hand, has a much bigger debt-load to account for when valuing the stock.

A third reason for buying AstraZeneca stock is the consistent record of shareholder dividend payments. One of the delights of the pharmaceutical sector is it tends to have less cyclicality than some other industries.

So, whether the economy is booming or busting, AstraZeneca tends to trade steadily, generating revenue, earnings and cash flow. And such constant finances can lead to a reliable stream of dividends for shareholders, as we’ve been seeing.

A solid-looking business

Right now, the forward-looking dividend yield is close to 2.8 for 2022. I admit that’s not a huge yield. But anticipated earnings should cover the payment more than twice. And it’s also backed by the strong cash flow the business enjoys. If earnings maintain their growth trajectory in the coming years, I think there’s a good chance we’ll see some decent annual rises in the dividend ahead.

I reckon the pandemic has underlined how vital the pharmaceutical sector is to society. So I’d be keen to get a solid-looking business such as AstraZeneca into my long-term diversified portfolio.

However, things may not work out as I hope for the business. Just a few years ago, for example, AstraZeneca was posting annual declines in earnings and battling a loss of revenue and profits because of patents running out. The so-called patent cliff faced by big pharmaceutical companies was well reported at the time. If the business stops posting earnings growth again, the valuation may start to look toppy and we could see share price declines leading to a losing investment in the stock.

But all shares come with risks. And in this case, I’d embrace the dangers and balance them against the firm’s growth potential. My plan would be to hold the stock for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Growth Shares

This FTSE 250 stock has beaten the index by around 10x over the last year

Jon Smith rates a FTSE 250 stock that has smashed the broader index performance and could keep going based on…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

B&M shares are at record lows! Is now the time to consider buying?

The retailer, demoted from the FTSE 100 to the FTSE 250 last year, continues to struggle. But are B&M shares…

Read more »

Investing For Beginners

2 reasons why the stock market could hit 10,000 points by December

Jon Smith explains how the makeup of the UK stock market and the current valuation could support a move towards…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Why this FTSE 100 rocket is this investment trust’s number 1 holding

A UK investment trust is certainly going against the grain by having this FTSE 100 share as a high-conviction holding…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

These 2 FTSE growth stocks jumped 8% and 4.5% today!

Ben McPoland takes a closer look at a pair of FTSE stocks that are performing really well recently. Why are…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

This under‑the‑radar FTSE 100 growth stock is also a secret dividend superstar!

Harvey Jones belatedly wakes up to a brilliant FTSE 100 growth stock that has an equally remarkable track record of…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Barratt Redrow share price plunges 9% on profits hit – time to consider buying?

Harvey Jones says FTSE 100 housebuilders continue to suffer with the Barratt Redrow share price slumping on a profit warning.…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Growth Shares

Why the next month could make or break the Lloyds share price

Jon Smith outlines two key events in coming weeks that could influence the Lloyds share price, leading him to make…

Read more »